Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes
|
By LabMedica International staff writers Posted on 29 Nov 2023 |

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating bacterial colonies with antibiotics, a process that is notably time-consuming, often taking several days to gauge bacterial resistance to a spectrum of antibiotics. This delay poses a significant challenge in urgent medical situations, like sepsis, where prompt treatment is crucial. As a result, clinicians are often compelled to either rely on their clinical judgment to prescribe specific antibiotics or administer a broad-spectrum antibiotic regimen. However, the use of ineffective antibiotics can exacerbate infections and potentially lead to increased AMR in the community. Now, researchers have reported significant progress in developing a rapid antimicrobial susceptibility test that can deliver results in as little as 30 minutes, marking a huge improvement over current standard methods.
A team of researchers from the University of Oxford (Oxford, UK) has created a method combining fluorescence microscopy with artificial intelligence (AI) to detect AMR. This technique involves training deep-learning models to scrutinize images of bacterial cells and identify structural changes when exposed to antibiotics. The method proved successful with various antibiotics, demonstrating a minimum accuracy of 80% on a per-cell analysis. The team applied this method to various clinical strains of E. coli, each exhibiting different resistance levels to the antibiotic ciprofloxacin. Impressively, the deep-learning models consistently and accurately identified antibiotic resistance, achieving results at least tenfold faster than current leading clinical methods.
With further development, this rapid testing method has the potential to enable more precise antibiotic treatments, reducing treatment durations, lessening side effects, and helping to curb the growth of AMR. The research team envisions future adaptations of this model for detecting resistance in clinical samples to a broader range of antibiotics. Their goal is to enhance the speed and scalability of this method for clinical application, as well as to modify it for use with various types of bacteria and antibiotics.
“Antibiotics that stop the growth of bacterial cells also change how cells look under a microscope, and affect cellular structures such as the bacterial chromosome,” said Achillefs Kapanidis, Professor of Biological Physics and Director of the Oxford Martin Program on Antimicrobial Resistance Testing. “Our AI-based approach detects such changes reliably and rapidly. Equally, if a cell is resistant, the changes we selected are absent, and this forms the basis for detecting antibiotic resistance.”
Related Links:
University of Oxford
Latest Pathology News
- AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells
- AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis
- New Review Highlights Intelligent Agents as Next Step for Digital Pathology
- Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
- AI Links Organ-Specific Aging Patterns in Histology to Blood-Based Signals
- 30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
- AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
- AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
- FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
- AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
- AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
- PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
- AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
- AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
- Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
- AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
Channels
Clinical Chemistry
view channelMultiprotein Plasma Panel Identifies Remission in Vasculitis
Vasculitis causes immune-mediated inflammation of blood vessel walls and can lead to kidney and lung damage. Clinicians rely on immunosuppressive drugs, but treatment carries significant side effects and... Read more
Rapid Urine Biomarker Panel Supports Better Kidney Transplant Decisions
Kidney transplantation remains constrained by organ scarcity and uncertainty about the quality of deceased-donor kidneys. In the United States, more than 92,000 people are awaiting a kidney transplant,... Read moreMolecular Diagnostics
view channel
Single Genetic Analysis Identifies Causes of Premature Ovarian Insufficiency
Premature ovarian insufficiency (POI) affects up to 3.5% of women and represents a major cause of infertility. In most cases, the underlying etiology remains unknown, making patient counseling and clinical... Read more
New Automation Platform Standardizes DNA and RNA Extraction Across Clinical Workflows
QIAGEN has introduced QIAsymphony Connect, an in vitro diagnostic (IVD)-compliant platform for automated clinical nucleic acid extraction. The system builds on more than 3,300 cumulative placements of... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Gut “Memory” May Explain Why IBD Flares Return
Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are characterized by recurring flare-ups that damage the intestinal mucosa and remain difficult to predict.... Read more
AI-Based Antibody Profiling Predicts Strength of COVID-19 Vaccine Response
Vaccine-induced protection can vary widely between individuals, creating uncertainty for clinicians, particularly in patients with immunosuppressive conditions. Demographic and health factors explain only... Read morePathology
view channel
AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells
Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more
AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis
Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more
New Review Highlights Intelligent Agents as Next Step for Digital Pathology
Digital pathology remains constrained by models that classify single images without mirroring how clinicians interrogate multiple slides, adjust magnification, and synthesize ancillary tests.... Read more
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read moreTechnology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read moreIndustry
view channelTumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring
NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more







